Four main classes of human tumor antigens recognized by T cells: 1- "Cancer-testis" antigens: non-mutated genes reactivated in neoplastic cells, but

Size: px
Start display at page:

Download "Four main classes of human tumor antigens recognized by T cells: 1- "Cancer-testis" antigens: non-mutated genes reactivated in neoplastic cells, but"

Transcription

1 Tumor antigens Andrea Anichini Human Tumors Immunobiology Unit, Dept. of Experimental Oncology and Molecular Medicine Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

2 Timeline of the discovery of the genes encoding tumor-associated antigens Four main classes of human tumor antigens recognized by T cells: 1- "Cancer-testis" antigens: non-mutated genes reactivated in neoplastic cells, but generally silenced in normal cells, with exception of male germ line cells and trophoblasts. 2- Tissue-specific self antigens. 3- Neoantigens resulting from nonsynomymous somatic mutations in neoplastic cells. 4- Normal genes overexpressed in cancer cells

3 A single tumor can express all classes of antigens: Tumor-associated antigens in B-NHL Tumor-associated antigens 1-Tumor-specific idiotype. 2-Shared antigens T cell recognition -Somatically mutated lymphoma Ig regions code for peptides recognized by patients T cells as tumor-specific antigens (Gricks 2001)- -non-mutated, germ-line V region sequences code for peptides recognized as shared antigens by patients T cells (Trojan, 2000). 3-B cell differentiation antigens. CD19 and CD20 encode peptides recognized by patients and healthy donors CD8+CTLs. (Grube 2004). 4-Over-expressed -Apoptosis regulators. Bcl-2 peptide-specific T cells in CLL patients (Andersen 2005) -Proteoglycans. Fibromodulin, overexpressed in CLL compared to normal B cells, encodes for peptides recognized by CTLs (Mayr, 2005)

4 Some antigens expressed by human melanoma Class Antigen peptide sequence HLA Cancer testis MAGE1 EADPTGHSY A1 MAGE3 FLWGPRALV A2 NY-ESO-1 SLLMWITQC A2 Mutated CDK4 ACDPHSGHFV A2 proteins β-catenin SYLDSGIHF A24 Cdc27 FSWAMDLDPKGA DR4 tissue specific antigens Tirosinasi YMDGTMSQV A2 gp100 ITDQVPFSV A2 Melan-A/Mart-1 AAGIGILTV A2 Trp-2 LLGPGRPYR A31

5 processing of a single protein can generate several peptides recognized by CD4+ and CD8+ T cells. HER-2 peptides recognized by T cells. HLA-Class II HLA-Class I (a) (b) (c) (d) (e) A33 A24 A11 A3 A Domain I Domain II Domain III Domain IV TM Tyrosine Kinase Regulatory Region Pertuzumab binding site Herceptin binding site bcr (a),(b),(c),(d),(e): distinct HLA Class II alleles and sometimes promiscuous epitopes

6 One gene, several tumor antigens, and different T and B subsets that recognize them HLA Class II CD4 Treg HLA Class I - CD8 - + HLA Class II CD4 TH B +

7 The same protein expressed in neoplastic cells can be target of B and T cells: immune response to tumors is integrated. B cell response T cell response HLA-peptide Comples TCR T T T

8 Biomarkers of response to anti-ctla-4 Pre-existing antibody response and T/B integrated response to NY-ESO-1 associated with clinical benefit to anti-ctla-4

9 How MHC Class I- peptide complexes are generated

10 MHC Class I vs MHC Class II antigen processing pathwyas

11 How the TCR "sees" the MHC-peptide complex CDR CDR peptide TCR-A TCR-B

12 How the TCR "sees" the MHC-peptide complex CDR3 CDR3 peptide

13 Molecular mechanisms that generate antigens recognized by T cells on tumor cells DNA mrna Protein Peptide Peptide Peptide (epitope o agretope*) (cryptic promoter) Peptide 4 (alternative orf) 5 Peptide (intron retention) 6 Peptide (post-traslational modification) *n.b.epitope: part of the peptide that interacts with the TCR agretope: part of the peptide that interacts with the HLA molecule

14 Protein and peptide surgery New mechanisms generate TAA recognized by T cells... Nature 427:252, Vigneron et al. Science 304:587, 2004 An antigenic peptide produced by peptide splicing in the proteasome R T K A W N R Q L Y P E W bibliografia: Science Science 304:587 Nature 427:252 R T K Q L Y P E W

15 Imagine you are in 1996 and you want to clone a tumor antigen

16 Cloning of tumor antigen genes recognized by patients' antibodies: SEREX approach tumor mrna cdna libraries in expression vectors Bacteria Screening by antibodies from patients' serum serex : serological analysis of recombinant cdna expression libraries

17 Antigen classes recognized by B cells and identified by SEREX 1. Cancer testis (CT) ags Mages NY-ESO-1 HOM-Mel-40/SSX2 CT7 SCP-1 BAGE GAGE NW-BR-3 2. mutated genes p53 LKB/STKII 3. amplified/overexpressed genes eif-4γ Carbonic anhydrase XII HER-2/neu 4.splicing variants 5. differentiation antigens (tissue-specific) Fibulin-1 NY-CO-37/PDZ-45 ING-1 NY-BR-1 Tyrosinase Galectin-4

18 Now you are in 2016 and want to identify new tumor antigens NPR1: Atrial natriuretic peptide receptor 1 KLGDFVA TL A TLHRRLGW T cell Rizvi et al. Mutational landscape determines sensitivity to PD-1 blockade in non small cell lung cancer. Science 348: , 2015

The next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK)

The next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK) The next steps for effective cancer immunotherapy and viral vaccines Peter Selby FACP(UK) Richard Alan Steve Sasha Matt Nav Vile Melcher Griffin Zougman Bentham Vasudev Adel Nick Gemma Liz Samson Hornigold

More information

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer) Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of

More information

A listing of human tumor antigens recognized by T cells: March 2004

A listing of human tumor antigens recognized by T cells: March 2004 A listing of human tumor antigens recognized by T cells: March 2004 update Luisa Novellino - Chiara Castelli - Giorgio Parmiani Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Via G.

More information

Human tumor antigens recognized by T lymphocytes: implications for cancer therapy

Human tumor antigens recognized by T lymphocytes: implications for cancer therapy Human tumor antigens recognized by T lymphocytes: implications for cancer therapy Rong-Fu Wang and Steven A. Rosenberg Surgery Branch, National Cancer institute, Bethesda, Maryland Abstract: The adoptive

More information

Basic Immunology. Lecture 26 th. Immunity against tumors

Basic Immunology. Lecture 26 th. Immunity against tumors Basic Immunology Lecture 26 th Immunity against tumors Neoplastic transformations are genetic alterations. Expression of cell surface antigens both self and non-self - seen by immune system. Ehrlich positive

More information

PEPTIDES AS TUMOR ANTIGENS

PEPTIDES AS TUMOR ANTIGENS REVIEW Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going? Giorgio Parmiani, Chiara Castelli, Piero Dalerba, Roberta Mortarini, Licia Rivoltini, Francesco M. Marincola,

More information

Two categories of immune response. immune response. infection. (adaptive) Later immune response. immune response

Two categories of immune response. immune response. infection. (adaptive) Later immune response. immune response Ivana FELLNEROVÁ E-mail: fellneri@hotmail.com, mob. 732154801 Basic immunogenetic terminology innate and adaptive immunity specificity and polymorphism immunoglobuline gene superfamily immunogenetics MHC

More information

Cancer Immunotherapy: Active Immunization Approaches

Cancer Immunotherapy: Active Immunization Approaches Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships

More information

Cancer Vaccines and Cytokines. Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology

Cancer Vaccines and Cytokines. Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology Cancer Vaccines and Cytokines Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology Disclosures I serve as the PI on a phase III trial sponsored by Galena BioPharma investigating

More information

Emerging Targets in Immunotherapy

Emerging Targets in Immunotherapy Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy

More information

From basic to tumour immunology for oncologists

From basic to tumour immunology for oncologists From basic to tumour immunology for oncologists Andrea Anichini Human Tumors Immunobiology Unit, Dept. of Experimental Oncology and Molecular Medicine Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

More information

Cancer Vaccine Collaborative 2002: Opening address

Cancer Vaccine Collaborative 2002: Opening address LATEST PAPERS SEARCH for PAPERS Printer-friendly PDF Comment(s) >Text >Contact author Cancer Immunity, Vol. 3 Suppl. 1, p. 1 (6 February 2003) Cancer Vaccine Collaborative 2002: Opening address Lloyd J.

More information

Immunology Lecture 4. Clinical Relevance of the Immune System

Immunology Lecture 4. Clinical Relevance of the Immune System Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor

More information

T cell Receptor. Chapter 9. Comparison of TCR αβ T cells

T cell Receptor. Chapter 9. Comparison of TCR αβ T cells Chapter 9 The αβ TCR is similar in size and structure to an antibody Fab fragment T cell Receptor Kuby Figure 9-3 The αβ T cell receptor - Two chains - α and β - Two domains per chain - constant (C) domain

More information

Cancer immunity and immunotherapy. General principles

Cancer immunity and immunotherapy. General principles 1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or

More information

Neoantigen Identification using ATLAS Across Multiple Tumor Types Highlights Limitations of Prediction Algorithms

Neoantigen Identification using ATLAS Across Multiple Tumor Types Highlights Limitations of Prediction Algorithms Neoantigen Identification using ATLAS Across Multiple Tumor Types Highlights Limitations of Prediction Algorithms Wendy Broom, Ph.D. Keystone: Translational Systems Immunology, Snowbird February 1st 2018

More information

Introduction. Introduction. Lymphocyte development (maturation)

Introduction. Introduction. Lymphocyte development (maturation) Introduction Abbas Chapter 8: Lymphocyte Development and the Rearrangement and Expression of Antigen Receptor Genes Christina Ciaccio, MD Children s Mercy Hospital January 5, 2009 Lymphocyte development

More information

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor

More information

Cyclin B1: Abnormal Self /Tumor Antigen. Laura Ann Vella. BA, University of Delaware. Submitted to the Graduate Faculty of

Cyclin B1: Abnormal Self /Tumor Antigen. Laura Ann Vella. BA, University of Delaware. Submitted to the Graduate Faculty of Cyclin B1: Abnormal Self /Tumor Antigen by Laura Ann Vella BA, University of Delaware Submitted to the Graduate Faculty of The School of Medicine in partial fulfillment of the requirements for the degree

More information

MHC class I MHC class II Structure of MHC antigens:

MHC class I MHC class II Structure of MHC antigens: MHC class I MHC class II Structure of MHC antigens: MHC class I antigens consist of a transmembrane heavy chain (α chain) that is non-covalently associated with β2- microglobulin. Membrane proximal domain

More information

Therapeutic Vaccines in Cancer

Therapeutic Vaccines in Cancer Therapeutic Vaccines in Cancer Kunle Odunsi, M.D., Ph.D. 1,2 Department of Gynecologic Oncology 1 Center for Immunotherapy 2 Roswell Park Cancer Institute Buffalo, NY Model of immune recognition of human

More information

ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics

ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics Precision Genomics for Immuno-Oncology Personalis, Inc. ACE ImmunoID When one biomarker doesn t tell the whole

More information

Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade

Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING

More information

Structure and Function of Antigen Recognition Molecules

Structure and Function of Antigen Recognition Molecules MICR2209 Structure and Function of Antigen Recognition Molecules Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will examine the major receptors used by cells of the innate and

More information

MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery

MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery Your Partner in Drug Discovery and Research MHC Tetramer Background T-Cell Receptors recognize and bind to complexes composed

More information

Leukemia (2007) 21, & 2007 Nature Publishing Group All rights reserved /07 $

Leukemia (2007) 21, & 2007 Nature Publishing Group All rights reserved /07 $ REVIEW (2007) 21, 1859 1874 & 2007 Nature Publishing Group All rights reserved 0887-6924/07 $30.00 www.nature.com/leu Department of Immunohematology and Blood Transfusion, Leiden University Medical Center,

More information

Major Histocompatibility Complex (MHC) and T Cell Receptors

Major Histocompatibility Complex (MHC) and T Cell Receptors Major Histocompatibility Complex (MHC) and T Cell Receptors Historical Background Genes in the MHC were first identified as being important genes in rejection of transplanted tissues Genes within the MHC

More information

Immune surveillance: The immune system can recognize and destroy nascent malignant cells

Immune surveillance: The immune system can recognize and destroy nascent malignant cells Immune surveillance: The immune system can recognize and destroy nascent malignant cells Control Escape APC T C T H B NKT NK Innate Tumor T cells are believed to play a major role in controlling tumor

More information

Tumor responses (patients responding/ patients treated)

Tumor responses (patients responding/ patients treated) Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing

More information

How T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do? Monoclonal antibody approach

How T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do? Monoclonal antibody approach How T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do By the early 1980s, much about T cell function was known, but the receptor genes had not been identified

More information

A second type of TCR TCR: An αβ heterodimer

A second type of TCR TCR: An αβ heterodimer How s recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do By the early 1980s, much about function was known, but the receptor genes had not been identified Recall

More information

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS 1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family

More information

Tumor Antigen, Tumor Immunogenicity and Immunization

Tumor Antigen, Tumor Immunogenicity and Immunization Society for Immunotherapy of Cancer 2012 Primer in Tumor Immunology and Biological Therapy of Cancer October 25 th, 2012, Bethesda, MD Tumor Antigen, Tumor Immunogenicity and Immunization Pedro Romero

More information

Immunotherapy on the Horizon: Adoptive Cell Therapy

Immunotherapy on the Horizon: Adoptive Cell Therapy Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest

More information

Andrea s SI Session PCB Practice Test Test 3

Andrea s SI Session PCB Practice Test Test 3 Practice Test Test 3 READ BEFORE STARTING PRACTICE TEST: Remember to please use this practice test as a tool to measure your knowledge, and DO NOT use it as your only tool to study for the test, since

More information

Immunological Tolerance

Immunological Tolerance Immunological Tolerance Introduction Definition: Unresponsiveness to an antigen that is induced by exposure to that antigen Tolerogen = tolerogenic antigen = antigen that induces tolerance Important for

More information

ACE ImmunoID. ACE ImmunoID. Precision immunogenomics. Precision Genomics for Immuno-Oncology

ACE ImmunoID. ACE ImmunoID. Precision immunogenomics. Precision Genomics for Immuno-Oncology ACE ImmunoID ACE ImmunoID Precision immunogenomics Precision Genomics for Immuno-Oncology Personalis, Inc. A universal biomarker platform for immuno-oncology Patient response to cancer immunotherapies

More information

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?

More information

Dissecting therapy-induced T-cell responses in melanoma

Dissecting therapy-induced T-cell responses in melanoma Dissecting therapy-induced T-cell responses in melanoma Tumor-infiltrating lymphocyte (TIL) therapy of melanoma TIL are grown from melanoma tumors Rapid Expansion Infusion of TIL + IL-2 Patient pretreated

More information

Adoptive Cell Therapy: Treating Cancer

Adoptive Cell Therapy: Treating Cancer Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells Steven A. Feldman, Ph.D. Surgery Branch National Cancer Institute NCT Conference Heidelberg, Germany September 24, 2013 Three

More information

Cancer Immunotherapy INTRODUCTION HUMAN TUMOR ANTIGENS. Cancer/Germ-Line Antigens

Cancer Immunotherapy INTRODUCTION HUMAN TUMOR ANTIGENS. Cancer/Germ-Line Antigens 14 Cancer Immunotherapy Steven A. Rosenberg, Paul R. Robbins, Giao Phan, Steven Feldman, and James Kochenderfer INTRODUCTION Progress in understanding basic aspects of cellular immunology and tumor host

More information

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent

More information

Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico.

Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Andrea Anichini Human Tumors Immunobiology Unit Dept. of Experimental Oncology and Molecular Medicine Immune checkpoint

More information

Society for Immunotherapy of Cancer (SITC)

Society for Immunotherapy of Cancer (SITC) Society for Immunotherapy of Cancer (SITC) Oncolytic Viruses and Their Application to Cancer Immunotherapy Ding Wang, MD, PhD Josephine Ford Cancer Institute Advances in Cancer Immunotherapy - Michigan

More information

Class I Ag processing. TAP= transporters associated with antigen processing Transport peptides into ER

Class I Ag processing. TAP= transporters associated with antigen processing Transport peptides into ER Antigen processing Class I Ag processing TAP= transporters associated with antigen processing Transport peptides into ER Proteosome degrades cytosolic proteins Large, multi-subunit complex Degrades foreign

More information

Andrea s Final Exam Review PCB 3233 Spring Practice Final Exam

Andrea s Final Exam Review PCB 3233 Spring Practice Final Exam NOTE: Practice Final Exam Although I am posting the answer key for this practice exam, I want you to use this practice to gauge your knowledge, and try to figure out the right answer by yourself before

More information

Darwinian selection and Newtonian physics wrapped up in systems biology

Darwinian selection and Newtonian physics wrapped up in systems biology Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid

More information

Principles of Adaptive Immunity

Principles of Adaptive Immunity Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors

More information

Central tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response

Central tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. Mechanisms of Immune Tolerance ACTIVATION (immunity) SUPPRESSION (tolerance)

More information

Mechanisms of Immune Tolerance

Mechanisms of Immune Tolerance Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. ACTIVATION (immunity) SUPPRESSION (tolerance) Autoimmunity Immunodeficiency

More information

Evidence for antigen-driven TCRβ chain convergence in the tumor infiltrating T cell repertoire

Evidence for antigen-driven TCRβ chain convergence in the tumor infiltrating T cell repertoire Evidence for antigen-driven TCRβ chain convergence in the tumor infiltrating T cell repertoire Geoffrey M. Lowman, PhD Senior Staff Scientist EACR - 02 July 2018 For Research Use Only. Not for use in diagnostic

More information

The Major Histocompatibility Complex (MHC)

The Major Histocompatibility Complex (MHC) The Major Histocompatibility Complex (MHC) An introduction to adaptive immune system before we discuss MHC B cells The main cells of adaptive immune system are: -B cells -T cells B cells: Recognize antigens

More information

Supporting Information

Supporting Information Supporting Information Chapuis et al. 10.1073/pnas.1113748109 SI Methods Selection of Patients, Targets, Isolation, and Expansion of Melanoma- Specific CTL Clones. Patients were HLA-typed, and their tumors

More information

Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy

Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,

More information

CHAPTER 9 BIOLOGY OF THE T LYMPHOCYTE

CHAPTER 9 BIOLOGY OF THE T LYMPHOCYTE CHAPTER 9 BIOLOGY OF THE T LYMPHOCYTE Coico, R., Sunshine, G., (2009) Immunology : a short course, 6 th Ed., Wiley-Blackwell 1 CHAPTER 9 : Biology of The T Lymphocytes 1. 2. 3. 4. 5. 6. 7. Introduction

More information

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and

More information

HARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER

HARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER OncoPept TM HARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER OncoPept identifies and delivers priortized T-cell neo-epitopes from the patient's tumor mutanome 2 What is OncoPept? OncoPept is an integrated

More information

The Adaptive Immune Response. T-cells

The Adaptive Immune Response. T-cells The Adaptive Immune Response T-cells T Lymphocytes T lymphocytes develop from precursors in the thymus. Mature T cells are found in the blood, where they constitute 60% to 70% of lymphocytes, and in T-cell

More information

Spontaneous. Tumour induction. Immunosuppression

Spontaneous. Tumour induction. Immunosuppression Tumor immunology is the study of : 1- The antigenic properties of the tumor cells 2- The host IR to these tumor cell 3- The immunologic consequences to the host of the growth of the malignant cells 4-

More information

Antibodies and T Cell Receptor Genetics Generation of Antigen Receptor Diversity

Antibodies and T Cell Receptor Genetics Generation of Antigen Receptor Diversity Antibodies and T Cell Receptor Genetics 2008 Peter Burrows 4-6529 peterb@uab.edu Generation of Antigen Receptor Diversity Survival requires B and T cell receptor diversity to respond to the diversity of

More information

Supplementary Information

Supplementary Information Supplementary Information High throughput epitope discovery reveals frequent recognition of neo-antigens by CD4 + T-cells in human melanoma Carsten Linnemann, Marit M. van Buuren, Laura Bies, Els M.E.Verdegaal,

More information

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 19: Tolerance, Autoimmunity, and Autoinflammation Prepared

More information

Adaptive Immune System

Adaptive Immune System Short Course on Immunology Adaptive Immune System Bhargavi Duvvuri Ph.D IIIrd Year (Immunology) bhargavi@yorku.ca Supervisor Dr.Gillian E Wu Professor, School of Kinesiology and Health Sciences York University,

More information

Cell Therapies. John HaanenMD PhD

Cell Therapies. John HaanenMD PhD Cell Therapies John HaanenMD PhD My disclosures I have provided consultation, attended advisory boards, and/or provided lectures for: Pfizer, Bayer, MSD, BMS, IPSEN, Novartis, Roche/Genentech, Astra Zeneca/MedImmune,

More information

T Cell Receptor Optimized Peptide Skewing of the T-Cell Repertoire Can Enhance Antigen Targeting

T Cell Receptor Optimized Peptide Skewing of the T-Cell Repertoire Can Enhance Antigen Targeting T Cell Receptor Optimized Peptide Skewing of the T-Cell Repertoire Can Enhance Antigen Targeting Julia Ekeruche-Makinde 1*, Mathew Clement 1*, David K Cole 1*, Emily S J Edwards 1, Kristin Ladell 1, John

More information

Rational approaches to human cancer immunotherapy

Rational approaches to human cancer immunotherapy Rational approaches to human cancer immunotherapy Ian D. Davis, Michael Jefford, Phillip Parente, and Jonathan Cebon Ludwig Institute for Cancer Research, Austin & Repatriation Medical Centre, Heidelberg,

More information

Immunocore Ltd isbtc Washington 30 th October 2009

Immunocore Ltd isbtc Washington 30 th October 2009 Ltd isbtc Washington 30 th October 2009 Bent Jakobsen Chief Scientific Officer Breaking immune tolerance to cancer The immune system has more cytotoxic potential and versatility than can be achieved with

More information

Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning

Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,

More information

Defensive mechanisms include :

Defensive mechanisms include : Acquired Immunity Defensive mechanisms include : 1) Innate immunity (Natural or Non specific) 2) Acquired immunity (Adaptive or Specific) Cell-mediated immunity Humoral immunity Two mechanisms 1) Humoral

More information

Self Tolerance and MHC Restriction. Dr. Issa Abu-Dayyeh

Self Tolerance and MHC Restriction. Dr. Issa Abu-Dayyeh Self Tolerance and MHC Restriction Dr. Issa Abu-Dayyeh How do we teach B and T cells not to recognise self antigens as dangerous? How do we restrict T cells to recognise only Ags presented on a self MHC

More information

Attribution: University of Michigan Medical School, Department of Microbiology and Immunology

Attribution: University of Michigan Medical School, Department of Microbiology and Immunology Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution

More information

Immunotherapy: The Newest Treatment Route

Immunotherapy: The Newest Treatment Route Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William

More information

- Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases.

- Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases. 암의면역치료 권병세 Immunotheraphy - Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases. - Applied for the treatment of cancer, autoimmune diseases, transplant rejection,

More information

Foreign antigens in human cancers

Foreign antigens in human cancers Foreign antigens in human cancers Lorenzo Fanchi PhD student, Ton Schumacher Lab ESMO Preceptorship on Immuno-Oncology May 26th, 2017 IMMUNE CHECKPOINT INHIBITION SHOWS CLINICAL BENEFIT IN DIFFERENT TUMOR

More information

Follicular Lymphoma. ced3 APOPTOSIS. *In the nematode Caenorhabditis elegans 131 of the organism's 1031 cells die during development.

Follicular Lymphoma. ced3 APOPTOSIS. *In the nematode Caenorhabditis elegans 131 of the organism's 1031 cells die during development. Harvard-MIT Division of Health Sciences and Technology HST.176: Cellular and Molecular Immunology Course Director: Dr. Shiv Pillai Follicular Lymphoma 1. Characterized by t(14:18) translocation 2. Ig heavy

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle   holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/39812 holds various files of this Leiden University dissertation Author: Buuren, Marit M. van Title: Analysis of the neo-antigen specific T cell response

More information

Antigen Recognition by T cells

Antigen Recognition by T cells Antigen Recognition by T cells TCR only recognize foreign Ags displayed on cell surface These Ags can derive from pathogens, which replicate within cells or from pathogens or their products that cells

More information

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop

More information

Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human melanoma

Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human melanoma Cancer Immun 1424-9634Academy of Cancer Immunology Cancer Immunity (2 April 2009) Vol. 9, p. 3 Copyright 2009 by Martin C. Mihm Jr. 090101 Review Focus on TILs: Prognostic significance of tumor infiltrating

More information

Exploring Therapeutic Combinations with anti-ctla-4 Antibody

Exploring Therapeutic Combinations with anti-ctla-4 Antibody Exploring Therapeutic Combinations with anti-ctla-4 Antibody Padmanee Sharma, MD, PhD Associate Professor GU Medical Oncology and Immunology M. D. Anderson Cancer Center isbtc Hot Topic Symposium October

More information

Tumor Microenvironment and Immune Suppression

Tumor Microenvironment and Immune Suppression Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation

More information

Potential cross reactions between HIV 1 specific T cells and the microbiome. Andrew McMichael Suzanne Campion

Potential cross reactions between HIV 1 specific T cells and the microbiome. Andrew McMichael Suzanne Campion Potential cross reactions between HIV 1 specific T cells and the microbiome Andrew McMichael Suzanne Campion Role of the Microbiome? T cell (and B cell) immune responses to HIV and Vaccines are influenced

More information

LESSON 2: THE ADAPTIVE IMMUNITY

LESSON 2: THE ADAPTIVE IMMUNITY Introduction to immunology. LESSON 2: THE ADAPTIVE IMMUNITY Today we will get to know: The adaptive immunity T- and B-cells Antigens and their recognition How T-cells work 1 The adaptive immunity Unlike

More information

NIH Public Access Author Manuscript Science. Author manuscript; available in PMC 2008 March 12.

NIH Public Access Author Manuscript Science. Author manuscript; available in PMC 2008 March 12. NIH Public Access Author Manuscript Published in final edited form as: Science. 2006 October 6; 314(5796): 126 129. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard

More information

Supplementary Table 1. Functional avidities of survivin-specific T-cell clones against LML-peptide

Supplementary Table 1. Functional avidities of survivin-specific T-cell clones against LML-peptide Supplementary Table 1. Functional avidities of survivin-specific T-cell clones against LML-peptide pulsed T2 cells. clone avidity by 4-hour 51 Cr-release assay 50% lysis at E:T 10:1 [LML peptide, M] #24

More information

Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning

Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu Director & Associate

More information

all of the above the ability to impart long term memory adaptive immunity all of the above bone marrow none of the above

all of the above the ability to impart long term memory adaptive immunity all of the above bone marrow none of the above 1. (3 points) Immediately after a pathogen enters the body, it faces the cells and soluble proteins of the innate immune system. Which of the following are characteristics of innate immunity? a. inflammation

More information

Current practice, needs and future directions in immuno-oncology research testing

Current practice, needs and future directions in immuno-oncology research testing Current practice, needs and future directions in immuno-oncology research testing Jose Carlos Machado IPATIMUP - Porto, Portugal ESMO 2017- THERMO FISHER SCIENTIFIC SYMPOSIUM Immune Therapies are Revolutionizing

More information

A Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients

A Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients A Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients Immunotherapy Biomarkers: Overcoming the Barriers NIH, Bethesda, April

More information

Antigen-Independent B-Cell Development Bone Marrow

Antigen-Independent B-Cell Development Bone Marrow Antigen-Independent B-Cell Development Bone Marrow 1. DNA rearrangements establish the primary repertoire, creating diversity 2. Allelic exclusion ensures that each clone expresses a single antibody on

More information

Immunotherapy Using T Cell Defined Tumor Antigens for Melanoma

Immunotherapy Using T Cell Defined Tumor Antigens for Melanoma Microbiol. Immunol., 42(12), 803-813, 1998 Minireview Immunotherapy Using T Cell Defined Tumor Antigens for Melanoma Yutaka Kawakami Division of Cellular Signaling, Institute for Advanced Medical Research,

More information

Current Tumor Immunotherapy

Current Tumor Immunotherapy Current Tumor Immunotherapy Part 1: On the preclinical and clinical efficacy of the current cancer vaccines. Part 2: The critical role of cancer vaccines in new integrative approaches. The State of the

More information

T cell maturation. T-cell Maturation. What allows T cell maturation?

T cell maturation. T-cell Maturation. What allows T cell maturation? T-cell Maturation What allows T cell maturation? Direct contact with thymic epithelial cells Influence of thymic hormones Growth factors (cytokines, CSF) T cell maturation T cell progenitor DN DP SP 2ry

More information

The functional investigation of the interaction between TATA-associated factor 3 (TAF3) and p53 protein

The functional investigation of the interaction between TATA-associated factor 3 (TAF3) and p53 protein THESIS BOOK The functional investigation of the interaction between TATA-associated factor 3 (TAF3) and p53 protein Orsolya Buzás-Bereczki Supervisors: Dr. Éva Bálint Dr. Imre Miklós Boros University of

More information

κ λ Antigen-Independent B-Cell Development Bone Marrow Ordered Rearrangement of Ig Genes During B-Cell Development in the Bone Marrow

κ λ Antigen-Independent B-Cell Development Bone Marrow Ordered Rearrangement of Ig Genes During B-Cell Development in the Bone Marrow Antigen-Independent B-Cell Development Bone Marrow 1. DNA rearrangements establish the primary repertoire, creating diversity 2. Allelic exclusion ensures that each clone expresses a single antibody on

More information

Adoptive T Cell Therapy:

Adoptive T Cell Therapy: Adoptive T Cell Therapy: A Paradigm for Combination Strategies Cassian Yee MD Professor Melanoma Medical Oncology Immunology Director Solid Tumor Cell Therapy cyee@mdanderson.org skype name: tcelltherapy

More information

Immune surveillance hypothesis (Macfarlane Burnet, 1950s)

Immune surveillance hypothesis (Macfarlane Burnet, 1950s) TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,

More information

Autoimmune diseases. Autoimmune diseases. Autoantibodies. Autoimmune diseases relatively common

Autoimmune diseases. Autoimmune diseases. Autoantibodies. Autoimmune diseases relatively common Autoimmune diseases Fundamental abnormality: the adaptive immune system is triggered by self antigens to initiate a sustained immune response against self molecules that results in tissue injury Specificity

More information

Immune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine

Immune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine Immune Tolerance Kyeong Cheon Jung Department of Pathology Seoul National University College of Medicine Immune tolerance Unresponsiveness to an antigen that is induced by previous exposure to that antigen

More information

Immunology for the Rheumatologist

Immunology for the Rheumatologist Immunology for the Rheumatologist Rheumatologists frequently deal with the immune system gone awry, rarely studying normal immunology. This program is an overview and discussion of the function of the

More information